Waverly Advisors LLC cut its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 31.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,265 shares of the conglomerate’s stock after selling 27,240 shares during the period. Waverly Advisors LLC’s holdings in Danaher were worth $11,479,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. EP Wealth Advisors LLC purchased a new position in shares of Danaher during the second quarter worth $3,807,000. Northwestern Mutual Wealth Management Co. boosted its holdings in Danaher by 303.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after acquiring an additional 186,584 shares during the period. Puzo Michael J purchased a new stake in Danaher during the second quarter worth about $8,624,000. Madison Asset Management LLC acquired a new stake in shares of Danaher during the second quarter worth about $85,451,000. Finally, First Nebraska Trust Co purchased a new position in shares of Danaher in the second quarter valued at approximately $14,106,000. Institutional investors and hedge funds own 79.05% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Evercore reissued an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. HSBC decreased their target price on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Piper Sandler began coverage on Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price for the company. Finally, Guggenheim cut their price target on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $228.91.
Danaher Trading Down 0.1%
NYSE DHR opened at $205.06 on Thursday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm has a 50 day moving average of $202.55 and a two-hundred day moving average of $192.08. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $144.15 billion, a PE ratio of 36.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.78.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.77 EPS. As a group, research analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.
Danaher Profile
Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.
The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.
Featured Articles
- Five stocks we like better than Danaher
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
